Biogen Halts Plans to Develop Tysabri for Stroke After Phase IIb Trial Flop Post author:Sam Post published:February 6, 2018 Post category:BioPharma Natalizumab did not demonstrate improvement in clinical outcomes compared to placebo. Source: BioSpace You Might Also Like Swift Biosciences Doubles Michigan HQ Space And Opens Up Shop In San Francisco October 5, 2017 Novartis Eyes 2019 for Launch of Investigational nAMD treatment February 21, 2018 Achaogen COO Promoted to Top Post, Effective Jan. 1, 2018 December 11, 2017
